Merck shareholders bless deal for Schering

It's official: Merck got shareholder approval for its $41 billion merger with Schering-Plough, with preliminary vote results showing that more than 99 percent of the stockholders gave a thumbs-up to the deal. Release

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.